CAS: 14080-32-1; 5-Nitropyrimidine

相似化合物

591-55-9 2222933-95-9 3073-77-6

上下游产品

CAS号3073-77-6 2-氨基-5-硝基嘧啶 | CAS号14001-69-5 2-甲氧基-5-硝基嘧啶 | CAS号4214-76-0 2-氨基-5-硝基吡啶 | CAS号14080-34-3 2-甲基-5-硝基嘧啶 | CAS号21901-34-8 2-羟基-3-甲基-5-硝基吡啶 | CAS号21203-68-9 2-甲基-5-硝基吡啶 | CAS号1450-76-6 2-羟基-5-硝基苯乙酮 | CAS号16475-85-7 2'-Hydroxy-4'-m... | CAS号68541-87-7 1-(2-methyl-5-n... | CAS号31309-11-2 2-Amino-5-nitro...

(2-肼基-5-硝基嘧啶-4-基)肼置于溶剂黄146,Silver Carbonate体系中,用 氯仿,水 用作溶剂,化学反应 1.5H,以21%的收率获得5-硝基嘧啶
参考文献:电子不足的杂芳烃盐:氧化中过氧化氢活化的有机催化工具
标题:电子不足的杂芳烃盐:氧化中过氧化氢活化的有机催化工具
摘要:制备了一系列的单取代的嘧啶鎓和吡嗪鎓三氟甲磺酸酯和3,5-二取代的吡啶鎓三氟甲磺酸酯,并使用硫氧化作为模型反应,对过氧化氢的简单氧化催化剂进行了测试.它们的催化效率在很大程度上取决于取代基的类型,并且对于具有吸电子基团的衍生物而言是显着的,其反应性与黄酮盐相当,后者是氧合作用的主要有机催化剂.由于它们的高稳定性和非常好的可及性,4-(三氟甲基)嘧啶鎓和3,5-二硝基吡啶鎓三氟甲磺酸盐是选择的催化剂,并显示出催化脂肪族和芳香族硫化物氧化为亚砜的作用,定量转化率高,制备产率高,并且具有优异的性能.化学选择性.K R +值(p K R + <5)和较小的负还原电位(e Red >-0.5 V).在催化氧化过程中原位形成的过氧化氢加合物充当底物氧化剂.通过在b3Lyp / 6-311 ++ G(d,P)水平上的计算获得的从这些杂环氢过氧化物到硫代苯甲醚的转移的吉布斯自由能表明,它们是比烷基氢过氧化
Doi:10.1021/jo502865F

专利信息

专利号:US-2003162992-A1
优先权日:2001-12-14
标 题 :Preparation of intermediates useful in the synthesis of antiviral nucleosides
发明人：WATANABE KYOICHI A; DU JINFA
摘要:The present invention is an efficient process for the manufacture of α-acyloxyacetaldehyde, a key intermediate in the synthesis of 1,3-oxathiolane and 1,3-dioxolane nucleosides.

专利号:EP-1501848-B1
优先权日:2002-05-08
标 题 :Synthesis of locked nucleic acid derivatives
发明人：SORENSEN MADS DETLEF; WENGEL JESPER; KOCH TROELS; CHRISTENSEN SIGNE M; ROSENBOHM CHRISTOPH; PEDERSEN DANIEL SEJER
权利人:SANTARIS PHARMA AS
摘要:The invention relates to a novel strategy for the synthesis of Locked Nucleic Acid derivatives, such as alpha-L-oxy-LNA, amino-LNA, alpha-L-amino-LNA, thio-LNA, alpha-L-thio-LNA, seleno-LNA and methylene LNA, which provides scalable high yielding reactions utilising intermediates that also can produce other LNA analogues such as oxy-LNA. Also, the compounds of the formula X are important intermediates that may be reacted with varieties of nucleophiles leading to a wide variety of LNA analogues. (Formula I)

专利号:US-7105666-B2
优先权日:2002-06-27
标 题:Synthesis of purine derivatives
发明人：HAMMARSTROEM LARS G J; KRAUSS NANCY ELISABTH; LABADIE SHARADA SHENVI; SMITH DAVID BERNARD; TALAMAS FRANCISCO XAVIER
权利人:ROCHE PALO ALTO LLC
摘要:The present invention provides a method for producing 2-, 6-, 8- and 9-substituted purine compounds from 4,6-dihalo-5-nitro-2-alkyl-pyrimidine compounds in solution or by solid phase techniques. The present process provides for the sequential introduction of amine substituents at the 4- and 6-positions, displacement of an alkylsulfony group at the 2-position of the pyrimidine, reduction of the nitro group and formation of the imidazole portion of the purine compound. Furthermore, the methods of the present invention are ideally suited to the preparation of a library of purine compounds.

专利号:US-7582748-B2
优先权日:2003-03-20
标题:Methods of manufacture of 2′-deoxy-β-L-nucleosides
发明人：RABI JAIME A
权利人:MICROBIOL QUIMICA FARMACEUTICA
摘要:The present invention relates to the synthesis of 2′-deoxy-β-L-thymidine, 2′-deoxy-β-L-uridine and 2′-deoxy-β-L-cytidine, and their derivatives, such as the 3′-O-acyl or 3′,5′-O-diacyl prodrugs, including the 3′-O-L-aminoacyl and 3′,5′-O-L-diaminoacyl prodrugs, and particularly the 3′-O-L-valinyl and 3′,5′-O-L-divalinyl prodrugs.

专利号:US-5401844-A
优先权日:1983-04-11
标 题 :Regulation of enzymes which utilize tetrahydrobiopterin or tetrahydrofolate cofactors with 6,6-disubstituted-tetrahydropteridines
发明人：AYLING JUNE E; BAILEY STEVEN W
权利人:UNIV SOUTH ALABAMA
摘要:6-[2'-Amino-2',2'-disubstituted-ethylamino]-pyrimidines of the structure: ##STR1## in which X=H, NH 2 or NO 2 , which are novel intermediates in the synthesis of quinoid 6,6-disubstituted-dihydro- and 6,6-disubstituted-tetrahydro-pteridines, are claimed.

专利号:EP-0609960-B1
优先权日:1989-09-15
标 题 :New N-heteroarylamide derivatives as inhibitors of acyl coenzyme A: cholestrol acyl transferase
发明人：MCCARTHY PETER A; HAMANAKA ERNEST S; WALKER FREDERICK J; CHANG GEORGE; TRUONG THIEN
权利人:PFIZER
摘要:Compounds of the formula the pharmaceutically acceptable salts thereof, wherein Q and R<1> are as defined below, and novel carboxylic acid and acid halide intermediates used in the synthesis of such compounds. The compounds of formula I are inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and antiatherosclerosis agents.